Clinical Trial Update: Study to Assess Xevinapant in Preoperative Subjects With Recurrent High-Grade Glioma (rHGG) [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating Xevinapant in preoperative patients with recurrent high-grade glioma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• High-grade Glioma

Drugs mentioned

• Xevinapant (Xevinapant)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Recurrent High-grade Glioma | Phase 1 | Status: WITHDRAWN